Regulation of cellular Cyclin D1 gene by arsenic is mediated through miR-2909

Gene

Volumn 522, Issue 1, 2013, Pages 60-64

  Sharma, M ^a   Sharma, S ^a   Arora, M ^a   Kaul, Deepak ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Arsenic; Genomics; Human PBMCs; Splice switching

Indexed keywords

ARSENIC; CYCLIN D1; KRUPPEL LIKE FACTOR 4; MICRORNA; MIR 2909; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ADENOID CYSTIC CARCINOMA; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); GENE EXPRESSION; GENETIC REGULATION; HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARSENIC; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENES, BCL-1; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, B-CELL; MICRORNAS; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84876962187     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.03.058     Document Type: Article

References (26)

1. Abernathy C.O., Thomas D.J., Calderon R.L. Health effects and risk assessment of arsenic. J. Nutr. 2003, 133:1536S-1538S.
2. Beezhold K., et al. miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis. Toxicol. Sci. 2011, 123:411-420.
3. Brocke-Heidrich K., et al. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene 2006, 25:7297-7304.
4. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
5. Chou W.-C., Chen H.-Y., Yu S.-L., Cheng L., Yang P.-C., Dang C.V. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood 2005, 106:304-310.
6. Donnellan R., Chetty R. Cyclin D1 and human neoplasia. Mol. Pathol. 1998, 51:1-7.
7. Eruslanov E., Kusmartsev S. Identification of ROS using oxidized DCFDA and flow-cytometry. Advanced Protocols in Oxidative Stress II 2010, 57-72. Humana Press, Totowa, NJ. D. Armstrong (Ed.).
8. Feng Y.-S., et al. Role of Kruppel-like factor 4 in regulating the expression of IL-6 induced by LPS*. Prog. Biochem. Biophys. 2009, 36:1313-1318.
9. Gilmore T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006, 25:6680-6684.
10. Gloire G., Legrand-Poels S., Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 2006, 72:1493-1505.
11. Hövelmeyer N., et al. Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD. J. Exp. Med. 2007, 204:2615-2627.
12. Hu W., et al. Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma. Clin. Cancer Res. 2009, 15:5688-5695.
13. Jomova K., et al. Arsenic: toxicity, oxidative stress and human disease. J. Appl. Toxicol. 2011, 31:95-107.
14. Jono H., et al. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. J. Biol. Chem. 2004, 279:36171-36174.
15. Kaul D., Hussain A. Cellular AATF gene encodes a novel miRNA that can contribute to HIV-1 latency. Indian J. Biochem. Biophys. 2009, 46:237-240.
16. Kligerman A.D., Tennant A.H. Insights into the carcinogenic mode of action of arsenic. Toxicol. Appl. Pharmacol. 2007, 222:281-288.
17. Kovalenko A., Chable-Bessia C., Cantarella G., Israël A., Wallach D., Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003, 424:801-805.
18. Letašiová S., et al. Bladder cancer, a review of the environmental risk factors. Environ. Health 2012, 11(Suppl. 1):S11.
19. Massoumi R., Chmielarska K., Hennecke K., Pfeifer A., Fässler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006, 125:665-677.
20. Parkhomchuk D., et al. Transcriptome analysis by strand-specific sequencing of complementary DNA. Nucleic Acids Res. 2009, 37:e123.
21. Ren X., McHale C.M., Skibola C.F., Smith A.H., Smith M.T., Zhang L. An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. Environ. Health Perspect. 2011, 119:11-19.
22. Shie J.-L., Chen Z.Y., Fu M., Pestell R.G., Tseng C.-C. Gut-enriched Krüppel-like factor represses cyclin D1 promoter activity through Sp1 motif. Nucl. Acids Res. 2000, 28:2969-2976.
23. Tchounwou P.B., Patlolla A.K., Centeno J.A. Invited reviews: carcinogenic and systemic health effects associated with arsenic exposure-a critical review. Toxicol. Pathol. 2003, 31:575-588.
24. Tokar E.J., Diwan B.A., Waalkes M.P. Renal, hepatic, pulmonary and adrenal tumors induced by prenatal inorganic arsenic followed by dimethylarsinic acid in adulthood in CD1 mice. Toxicol. Lett. 2012, 209:179-185.
25. Wang F., Shi Y., Yadav S., Wang H. p52-Bcl3 complex promotes cyclin D1 expression in BEAS-2B cells in response to low concentration arsenite. Toxicology 2010, 273:12-18.
26. Zhao C.Q., Young M.R., Diwan B.A., Coogan T.P., Waalkes M.P. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:10907-10912.